Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
29 September 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
11 February 2025
Foley Ignite
Where is corporate venture capital headed in 2025, and will it lead to more M&A?
Corporate Venture Capital (CVC) investment is an increasingly used strategic tool that enables large corporations to make minority investments in startups that will complement and expand their existing products or services.
11 February 2025
Labor & Employment Law Perspectives
Illinois Takes Aim at Artificial Intelligence in Employment
In a significant move to regulate artificial intelligence (AI) in the workplace, the Illinois Legislature amended the Illinois Human Rights Act to address the growing use of AI at various points throughout the employment process.
18 February 2025
Events
Hellenic Innovation Network of New York: Innovation & Impact
Join Foley & Lardner LLP and the Hellenic Innovation Network in our New York office on February 18th for an evening of Innovation & Impact.